Article Text

Download PDFPDF
Original article
Population-based incidence of exudative age-related macular degeneration and ranibizumab treatment load
  1. Asbjorg Geirsdottir1,
  2. Oskar Jonsson1,
  3. Sigridur Thorisdottir1,
  4. Gudleif Helgadottir1,
  5. Fridbert Jonasson1,2,
  6. Einar Stefansson1,2,
  7. Haraldur Sigurdsson1,2
  1. 1Department of Ophthalmology, Landspitali—The National University Hospital of Iceland, Reykjavik, Iceland
  2. 2Department of Ophthalmology, University of Iceland, Faculty of Medicine, Reykjavik, Iceland
  1. Correspondence to Dr Haraldur Sigurdsson, Department of Ophthalmology, Landspitali—The National University Hospital of Iceland, 101 Reykjavik, Iceland; haraldsi{at}


Background/aims The use of intravitreal vascular endothelial growth factor antibodies for exudative age-related macular degeneration (AMD) has stressed ophthalmology services and drug budgets throughout the world. The authors study the population-based incidence of exudative AMD in Iceland and the use of intravitreal ranibizumab in a defined population.

Methods This is a prospective study of 439 consecutive patients aged 60 years and older with exudative AMD starting intravitreal ranibizumab for exudative AMD in Iceland from March 2007 to December 2009. All patients initially received three consecutive ranibizumab injections, with regular follow-up visits and re-treatment as needed.

Results In total, 517 eyes from 439 patients received treatment for exudative AMD (mean age 79 years). The annual incidence of exudative AMD in the population 60 years and older is 0.29%. The incidence increased with advancing age, double for patients 85 years and older compared with those 75–79 years. Approximately 2400 ranibizumab injections per 100 000 persons aged 60 years and older were given each year for exudative AMD.

Conclusions These data allow an estimation of the incidence of exudative AMD in a Caucasian population and the treatment load with ranibizumab, which may help plan anti-vascular endothelial growth factor treatment programmes and estimate costs.

  • AMD
  • Iceland
  • incidence
  • ranibizumab
  • treatment load
  • retina
  • physiology
  • neovascularisation
  • epidemiology
  • optic nerve
  • genetics
  • pharmacology
  • public health
  • treatment lasers
  • lacrimal drainage
  • orbit

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Competing interests None.

  • Ethics approval Ethics approval was provided by the Landspitali Ethics Committee and the Icelandic Data Protection Commission.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Linked Articles

  • At a glance
    Harminder S Dua Arun D Singh